{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:08:44Z","timestamp":1778504924256,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021546","name":"Suez University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021546","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. NAC has shown promise in reducing PTSD symptoms and cravings in veterans, according to recent trials. Our analysis aims to resolve the conflict between results and determine whether NAC is an effective add-on therapy for PTSD, AUD, and co-occurring PTSD\/AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD420251170956). We searched PubMed, Scopus, Cochrane CENTRAL, Embase, EBSCO, and the Web of Science for relevant studies. Only randomized placebo-controlled trials were included. The primary outcomes were severity of PTSD and alcohol craving, while secondary outcomes were anxiety, depression, and alcohol use patterns and biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven randomized, double-blind, placebo-controlled trials were included in this meta-analysis, enrolling a total of 566 participants. There were no significant differences between NAC and placebo in craving (SMD= -0.40, 95% CI [-1.05, 0.25],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.22, I\u00b2 = 56.1%). Regarding PTSD severity, the PCL scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD\u2009=\u20090.04, 95% CI [-0.40, 0.48],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.8) (I\u00b2 = 65.9%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.05), while the CAPS scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = -0.13, 95% CI [-0.50, 0.24],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.49) (I\u00b2 = 54.8%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.109). Leave-one-out sensitivity analysis showed that exclusion of the Back et al. (2025) study resulted in a significant effect favoring NAC (SMD = -0.35, 95% CI [-0.70, -0.01],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04), with no observed heterogeneity (I\u00b2 = 0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. However, the treatment is relatively safe. A noteworthy signal of potential efficacy for PTSD symptoms emerged in a sensitivity analysis, suggesting that the therapeutic promise of NAC should not be entirely dismissed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08124-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:04:29Z","timestamp":1778475869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3675-8951","authenticated-orcid":false,"given":"Mohamed Awad E.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8882-5116","authenticated-orcid":false,"given":"Mufreh","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-1417","authenticated-orcid":false,"given":"Yomna Emad","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1942-224X","authenticated-orcid":false,"given":"Nourhan","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3999-4301","authenticated-orcid":false,"given":"Aya","family":"Samy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9203-5107","authenticated-orcid":false,"given":"Omar","family":"Kassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3637-8922","authenticated-orcid":false,"given":"Khalid Radwan","family":"Alsaadany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2195-2353","authenticated-orcid":false,"given":"Mohamed Ezzat M.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"2","key":"8124_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.35946\/arcr.v39.2.03","volume":"39","author":"E Straus","year":"2018","unstructured":"Straus E, Haller M, Lyons RC, Norman SB. Functional and Psychiatric Correlates of Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder. Alcohol Res. 2018;39(2):121\u20139.","journal-title":"Alcohol Res"},{"issue":"13","key":"8124_CR2","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1017\/S0033291717000708","volume":"47","author":"KC Koenen","year":"2017","unstructured":"Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260\u201374.","journal-title":"Psychol Med"},{"issue":"Pt B","key":"8124_CR3","doi-asserted-by":"publisher","first-page":"109184","DOI":"10.1016\/j.drugalcdep.2021.109184","volume":"229","author":"T Slade","year":"2021","unstructured":"Slade T, Mewton L, O\u2019Dean S, Tibbetts J, Clay P, Isik A, et al. DSM-5 and ICD-11 alcohol use disorder criteria in young adult regular drinkers: Lifetime prevalence and age of onset. Drug Alcohol Depend. 2021;229(Pt B):109184.","journal-title":"Drug Alcohol Depend"},{"key":"8124_CR4","doi-asserted-by":"crossref","unstructured":"McCauley JL, Killeen T, Gros DF, Brady KT, Back SE. Posttraumatic Stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clin Psychol (New York). 2012;19(3).","DOI":"10.1111\/cpsp.12006"},{"issue":"9","key":"8124_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/01.nmd.0000235794.12794.8a","volume":"194","author":"SE Back","year":"2006","unstructured":"Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 2006;194(9):690\u20136.","journal-title":"J Nerv Ment Dis"},{"issue":"8","key":"8124_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1176\/appi.ajp.20240536","volume":"181","author":"A Shalev","year":"2024","unstructured":"Shalev A, Cho D, Marmar CR. Neurobiology and treatment of posttraumatic stress disorder. Am J Psychiatry. 2024;181(8):705\u201319.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"8124_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.psychres.2015.05.036","volume":"229","author":"M Furtado","year":"2015","unstructured":"Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 2015;229(1\u20132):37\u201348.","journal-title":"Psychiatry Res"},{"issue":"1","key":"8124_CR8","first-page":"15","volume":"59","author":"A Rodolico","year":"2024","unstructured":"Rodolico A, Aguglia A, Caponnetto P, et al. Depressive reactions following war-related trauma: a case series and a brief review of the literature. Riv Psichiatr. 2024;59(1):15\u201322.","journal-title":"Riv Psichiatr"},{"key":"8124_CR9","doi-asserted-by":"crossref","unstructured":"Tsermpini EE, Plemenita\u0161 Ilje\u0161 A, Dol\u017ean V. Alcohol-induced oxidative stress and the role of antioxidants in alcohol use disorder: a systematic review. Antioxidants (Basel). 2022;11(7).","DOI":"10.3390\/antiox11071374"},{"issue":"5","key":"8124_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40263-022-00907-3","volume":"36","author":"RCJ Bradlow","year":"2022","unstructured":"Bradlow RCJ, Berk M, Kalivas PW, Back SE, Kanaan RA. The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. CNS Drugs. 2022;36(5):451\u201382.","journal-title":"CNS Drugs"},{"issue":"3","key":"8124_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17425255.2017.1251580","volume":"13","author":"A Minarini","year":"2017","unstructured":"Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol. 2017;13(3):279\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"8124_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s43440-021-00283-7","volume":"73","author":"I Smaga","year":"2021","unstructured":"Smaga I, Frankowska M, Filip M. N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Pharmacol Rep. 2021;73(5):1205\u201319.","journal-title":"Pharmacol Rep"},{"issue":"11","key":"8124_CR13","doi-asserted-by":"publisher","first-page":"e1439","DOI":"10.4088\/JCP.15m10239","volume":"77","author":"SE Back","year":"2016","unstructured":"Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM, et al. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. J Clin Psychiatry. 2016;77(11):e1439\u201346.","journal-title":"J Clin Psychiatry"},{"key":"8124_CR14","doi-asserted-by":"crossref","unstructured":"Back SE, Gray K, Jarnecke AM, Saraiya TC, Santa Ana EJ, Killeen T, et al. N-Acetylcysteine for the treatment of co-occurring posttraumatic stress disorder and alcohol use disorder: a double-blind, randomized controlled Trial. J Clin Psychiatry. 2025;86(4).","DOI":"10.4088\/JCP.25m15803"},{"issue":"1","key":"8124_CR15","doi-asserted-by":"publisher","first-page":"e2823","DOI":"10.1002\/brb3.2823","volume":"13","author":"F Padoei","year":"2023","unstructured":"Padoei F, Mamsharifi P, Hazegh P, Boroumand H, Ostadmohammady F, Abbaszadeh-Mashkani S, et al. The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. Brain Behav. 2023;13(1):e2823.","journal-title":"Brain Behav"},{"key":"8124_CR16","doi-asserted-by":"publisher","first-page":"105961","DOI":"10.1016\/j.cct.2020.105961","volume":"91","author":"SE Back","year":"2020","unstructured":"Back SE, Gray K, Santa Ana E, Jones JL, Jarnecke AM, Joseph JE, et al. N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial. Contemp Clin Trials. 2020;91:105961.","journal-title":"Contemp Clin Trials"},{"issue":"7","key":"8124_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ajad.12620","volume":"26","author":"MS Duailibi","year":"2017","unstructured":"Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M, et al. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis. Am J Addict. 2017;26(7):660\u20136.","journal-title":"Am J Addict"},{"issue":"2","key":"8124_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.9758\/cpn.2021.19.2.282","volume":"19","author":"C-T Chang","year":"2021","unstructured":"Chang C-T, Hsieh P-J, Lee H-C, Lo C-H, Tam K-W, Loh E-W. Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials. Clin Psychopharmacol Neurosci. 2021;19(2):282\u201393.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"8124_CR19","doi-asserted-by":"crossref","unstructured":"Winterlind EL, Malone SG, Setzer MR, Murphy MA, Saunders D, Gray JC. N-acetylcysteine as a treatment for substance use cravings: a meta-analysis. medRxiv. 2024.","DOI":"10.1101\/2024.05.13.24306839"},{"issue":"3","key":"8124_CR20","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.","journal-title":"PLoS Med"},{"key":"8124_CR21","unstructured":"Cochrane Handbook for Systematic Reviews. of Interventions. Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current"},{"key":"8124_CR22","unstructured":"Rayyan. AI powered tool for systematic literature reviews. https:\/\/www.rayyan.ai\/"},{"issue":"6","key":"8124_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1037\/pas0001130","volume":"34","author":"DJ Lee","year":"2022","unstructured":"Lee DJ, Weathers FW, Thompson-Hollands J, Sloan DM, Marx BP. Concordance in PTSD symptom change between DSM-5 versions of the Clinician-Administered PTSD Scale (CAPS-5) and PTSD Checklist (PCL-5). Psychol Assess. 2022;34(6):604\u20139.","journal-title":"Psychol Assess"},{"issue":"1","key":"8124_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.18060\/1874","volume":"13","author":"JS Yarvis","year":"2012","unstructured":"Yarvis JS, Yoon E, Ameuke M, Simien-Turner S, Landers G. Assessment of PTSD in Older Veterans: The Posttraumatic Stress Disorder Checklist: Military Version (PCL-M). Adv Soc Work. 2012;13(1):185\u2013202.","journal-title":"Adv Soc Work"},{"issue":"8","key":"8124_CR25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289\u201395.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"8124_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/07347324.2015.1018778","volume":"33","author":"KA Hallgren","year":"2015","unstructured":"Hallgren KA, Owens MD, Brovko JM, Ladd BO, McCrady BS, Epstein EE. Trajectories of Drinking Urges During Individual- and Couple-based Cognitive-Behavioral Treatment for Alcohol Use Disorders. Alcohol Treat Q. 2015;33(2):161\u201384.","journal-title":"Alcohol Treat Q"},{"issue":"Suppl 11","key":"8124_CR27","first-page":"S454","volume":"63","author":"KL Smarr","year":"2011","unstructured":"Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S454\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"8124_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1590\/1516-4446-2012-1048","volume":"35","author":"Y-P Wang","year":"2013","unstructured":"Wang Y-P, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Rev Bras Psiquiatr. 2013;35(4):416\u201331.","journal-title":"Rev Bras Psiquiatr"},{"issue":"1","key":"8124_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0005-7967(96)00068-X","volume":"35","author":"TA Brown","year":"1997","unstructured":"Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther. 1997;35(1):79\u201389.","journal-title":"Behav Res Ther"},{"issue":"2","key":"8124_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0306-4603(86)90040-7","volume":"11","author":"MB Sobell","year":"1986","unstructured":"Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E. The reliability of a timeline method for assessing normal drinker college students\u2019 recent drinking history: utility for alcohol research. Addict Behav. 1986;11(2):149\u201361.","journal-title":"Addict Behav"},{"issue":"5","key":"8124_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/alcalc\/agad044","volume":"58","author":"KC Morley","year":"2023","unstructured":"Morley KC, Peruch S, Adams C, Towers E, Tremonti C, Watt J, et al. N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2023;58(5):553\u201360.","journal-title":"Alcohol Alcohol"},{"key":"8124_CR32","doi-asserted-by":"crossref","unstructured":"Shayani G, Raka J, Sonali J, Ravindra R, Ashwani Kumar M. Alcohol biomarkers and their relevance in detection of alcohol consumption in clinical settings. Int Arch Subst Abuse Rehabil. 2019;1(1).","DOI":"10.23937\/iasar-2017\/1710002"},{"issue":"1","key":"8124_CR33","first-page":"30","volume":"28","author":"K Peterson","year":"2004","unstructured":"Peterson K. Biomarkers for alcohol use and abuse\u2013a summary. Alcohol Res Health. 2004;28(1):30\u20137.","journal-title":"Alcohol Res Health"},{"key":"8124_CR34","doi-asserted-by":"crossref","unstructured":"Rama K, Jahagirdar V, Idalsoaga F, Blaney H, Rhoads SF, D\u00edaz LA, et al. Novel Biomarkers for Alcohol-associated liver disease and their implications across clinical settings. Clin Mol Hepatol. 2025.","DOI":"10.3350\/cmh.2025.0921"},{"issue":"7066","key":"8124_CR35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","volume":"313","author":"DG Altman","year":"1996","unstructured":"Altman DG, Bland JM. Detecting skewness from summary information. BMJ. 1996;313(7066):1200.","journal-title":"BMJ"},{"key":"8124_CR36","doi-asserted-by":"publisher","first-page":"115398","DOI":"10.1016\/j.psychres.2023.115398","volume":"327","author":"RA Kanaan","year":"2023","unstructured":"Kanaan RA, Oliver G, Dharan A, Sendi S, Maier A, Mohebbi M, et al. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD. Psychiatry Res. 2023;327:115398.","journal-title":"Psychiatry Res"},{"issue":"1","key":"8124_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00213-024-06656-z","volume":"242","author":"WB Logge","year":"2025","unstructured":"Logge WB, Haber PS, Hurzeler TP, Towers EE, Morley KC. The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study. Psychopharmacology. 2025;242(1):149\u201360.","journal-title":"Psychopharmacology"},{"key":"8124_CR38","first-page":"e20243541","volume":"47","author":"JB Schuch","year":"2025","unstructured":"Schuch JB, Hansen F, Hartmann T, Benzano D, Gomes HM, Moreira JCF, et al. A randomized, double-blind, placebo-controlled trial of N-acetylcysteine as an adjuvant treatment for alcohol use disorder. Rev Bras Psiquiatr. 2025;47:e20243541.","journal-title":"Rev Bras Psiquiatr"},{"key":"8124_CR39","doi-asserted-by":"crossref","unstructured":"Squeglia LM, Tomko RL, Baker NL, Kirkland AE, McClure EA, Gray KM. A Randomized Controlled Trial of N-acetylcysteine for adolescent and young adult alcohol use disorder. J Am Acad Child Adolesc Psychiatry. 2025.","DOI":"10.1016\/j.jaac.2025.09.025"},{"issue":"3","key":"8124_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","volume":"82","author":"EM Burnette","year":"2022","unstructured":"Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022;82(3):251\u201374.","journal-title":"Drugs"},{"key":"8124_CR41","doi-asserted-by":"publisher","first-page":"1462612","DOI":"10.3389\/fphar.2024.1462612","volume":"15","author":"M Cuocina","year":"2024","unstructured":"Cuocina M, Aiello G, Cutrufelli P, Rampello M, Rapisarda L, Rodolico A, et al. Effect of N-acetylcysteine on craving in substance use disorders (SUD): a meta-analysis of randomized controlled trials. Front Pharmacol. 2024;15:1462612.","journal-title":"Front Pharmacol"},{"issue":"1","key":"8124_CR42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306\u201333.","journal-title":"Hepatology"},{"issue":"9","key":"8124_CR43","doi-asserted-by":"publisher","first-page":"e091631","DOI":"10.1136\/bmjopen-2024-091631","volume":"15","author":"K Morley","year":"2025","unstructured":"Morley K, Arunogiri S, Connor JP, Clark PJ, Chatterton ML, Baillie A, et al. N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study). BMJ Open. 2025;15(9):e091631.","journal-title":"BMJ Open"},{"issue":"1","key":"8124_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12888-020-02793-9","volume":"20","author":"A Maier","year":"2020","unstructured":"Maier A, Dharan A, Oliver G, Berk M, Redston S, Back SE, et al. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. BMC Psychiatry. 2020;20(1):397.","journal-title":"BMC Psychiatry"},{"key":"8124_CR45","unstructured":"Rodolico A, et al. Metabolic modulators acting on oxidative stress and neuroinflammatory pathways in psychiatric disorders: a focus on N-acetylcysteine and acetyl-l-carnitine in neuropsychiatric manifestations associated with systemic conditions. Curr Neuropharmacol. 2025."},{"issue":"1","key":"8124_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10787-024-01616-7","volume":"33","author":"Ahmed Ramzi","year":"2025","unstructured":"Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology. 2025;33(1):105\u201319. https:\/\/doi.org\/10.1007\/s10787-024-01616-7.","journal-title":"Inflammopharmacology"},{"key":"8124_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.genhosppsych.2024.10.018","volume":"91","author":"T-R Peng","year":"2024","unstructured":"Peng T-R, Lin H-H, Tseng T-L, Huang Y-H, Tsai P-Y, Lin C-Y, et al. Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis. Gen Hosp Psychiatry. 2024;91:151\u20139.","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"8124_CR48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/acps.12862","volume":"137","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhang QE, Cai DB, Yang XH, Qiu Y, Ungvari GS, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137(5):391\u2013400.","journal-title":"Acta Psychiatr Scand"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08124-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:17:45Z","timestamp":1778501865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8124"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08124-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}